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Synopsis
We investigated MRI changes in quantitative T2 parameters in lesions and healthy tissue in men on active surveillance (AS) for prostate
cancer (PCa) taking dutasteride or placebo for six months. The protocol included a multi-echo sequence for quantification of the T2
relaxation times. A synthetic signal contrast (T2Q) between lesion and healthy tissue was assessed using quantitative T2 values. Signal
contrast was calculated using T2-weighted sequence (T2W contrast). No diﬀerences for T2W contrast were observed. A significant
correlation between T2Q and T2W contrast was shown. Dutasteride does not influence T2 contrast and relaxation in men on AS for PCa.
INTRODUCTION
Multiparametric magnetic resonance imaging (mpMRI) plays a crucial role in the diagnosis and risk stratification of men with prostate cancer (PCa).
High resolution T2-weighted imaging (T2-WI) is employed in the mpMRI protocol for detection of lesions. Quantitative measurements of tissue T2
relaxation time – which are not typically used in prostate mpMRI - can be of interest when evaluating the tumor response to therapy, since they can
provide additional insight into the changes in tumor microenvironment. Dutasteride reduces prostate volume, and there is evidence that it may delay
the rate of progression in men on active surveillance (AS) for PCa . Our aim was to evaluate the role of quantitative T2 outputs in men on AS exposed
to dutasteride .
METHODS
Forty men with PCa on AS were individually randomized (1:1) to daily placebo or dutasteride for 6 months. 3T mpMRI was performed at baseline and
after 6 months. In addition to the standard mpMRI protocol, quantitative T2 imaging was performed with a multi-echo approach based on the Carr-
Purcell-Meibom-Gill (CPMG) imaging sequence . The CPMG protocol was optimized to ensure a good compromise between in-plane spatial
resolution, the sampling of the T2 relaxation decay and the signal-to-noise ratio (Table 1). Regions of interest (ROIs) on the index lesion on the T2-
weighted high-resolution images were chosen. The ROI was copied and pasted in the non-cancerous peripheral (PZ) and transitional (TZ) zone, in
mirror position to the lesion (Fig. 1). The signal values from this sequence were defined as T2-weighted (T2W). The three ROIs were copied and
pasted on the multi-echo CPMG sequence. T2 data fitting was performed using MATLAB. For each patient, we measured the signal intensity of the
lesion (S ) and compared it to the signal intensity of presumed non-cancer tissue in mirror position on T2-WI. T2W contrast between a lesion in the
PZ and the non-cancerous tissue was defined as (S - S )/S  . To investigate whether there was a correlation between the T2-weighted and the
quantitative T2 imaging data, we calculated a ‘synthetic’ contrast (T2Q contrast) using the T2 values obtained from the CPMG data fitting. Median
baseline and 6-month T2 values and contrast were compared for each arm (Wilcoxon and Mann-Whitney tests). The relationship between T2W and
T2Q contrast was assessed (Spearman’s correlation).
RESULTS
The value of T2 relaxation time in healthy prostate and in lesions did not change following dutasteride [baseline T2 lesion: 80.5 ms (74.2-89.5 ms); at 6
months: 81.9 ms (72.4-85.8 ms]. Furthermore, no significant diﬀerences for T2W contrast at baseline and after 6 months were observed, both in the
placebo [0.40 (0.29-0.49) vs 0.43 (0.25-0.49); p=0.881] and dutasteride arm [0.35 (0.24-0.47) vs 0.37 (0.22-0.44); p = 0.668]. Additionally, there were
no significant diﬀerences in T2W contrast between the placebo and the dutasteride arm at baseline [0.40 (0.29-0.49) vs 0.35 (0.24-0.47); p = 0.409]
and after 6 months [0.43 (0.25-0.49) vs 0.37 (0.22-0.44); p=0.372]. There was a significant, positive correlation between T2W and T2Q contrast values
(r=0.786; p < 0.001), as shown in Fig. 2.
DISCUSSION
It is known that antiandrogen therapy aﬀects prostatic tissues, which inevitably aﬀects the interpretation of mpMRI studies. Our study indicated that
the tissue T2 relaxation time, T2Q contrast and T2W contrast values appear to be unaﬀected by exposure to dutasteride. Considerable variability of
the contrast in the T2-WI was observed; same consideration applies to quantitative T2 measurements, where diﬀerent T2 values were measured in
diﬀerent patients. The correlation found between the contrast measured on the T2-weighted images and the “synthetic” contrast calculated from the
quantitative T2 measurement indicates that the variability could be partly explained by inter-individual diﬀerences. Following our definition of contrast,
we could consider this parameter as a surrogate of the conspicuity of the lesion on T2-WI. It follows that the use of dutasteride does not seem to
influence lesion conspicuity on T2-WI (i.e. the lesion is still detectable after treatment). This suggests that the drug may not impair our ability to
measure and monitor tumor volume in AS.
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Figures
Table 1: MRI parameters of the Carr-Purcell-Meiboom-Gill (CPMG) sequence for quantitative T2 imaging.
Figure 1: MR images of the prostate of a 69-year-old man with a PSA of 5.83 ng/ml and a Gleason 3+4 tumor in the mid-right peripheral zone at entry
biopsy. The region of interest (ROI) for quantitative T2 analysis is here illustrated. Three ROIs (lesion, non-cancerous peripheral and transitional zones)
were drawn on the high-resolution T2 image. These ROIs were then copied and pasted on the multi-echo images.
Figure 2: Scatter plot of contrast from high-resolution T2-weighted (T2W) and quantitative T2 (T2Q) imaging, showing a positive correlation (r=0.786; p
< 0.001).
